piceid (Tokyo Chemical Industry)
Structured Review

Piceid, supplied by Tokyo Chemical Industry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piceid/piceid/pmc12743528-37-6-12
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "An accessible HPLC-DAD method for the direct detection of acrolein-trapping compounds in complex plant matrices ☆ "
Article Title: An accessible HPLC-DAD method for the direct detection of acrolein-trapping compounds in complex plant matrices
Journal: MethodsX
doi: 10.1016/j.mex.2025.103747
Figure Legend Snippet: Chromatographic profile of the ten-component mixture, with detection at a wavelength of 280 nm. The upper chromatogram corresponds to the negative control (0 mM acrolein), while the lower chromatogram represents the mixture following pretreatment with 5 mM acrolein. 1: protocatechuic acid, 2: esculin, 3: catechin, 4: epicatechin, 5: coumaric acid, 6: piceid, 7: rutin, 8: phloridzin, 9: resveratrol, 10: phloretin. Acrolein-trapping compounds are highlighted in red.
Techniques Used: Negative Control
Related Articles
other:Article Title: Ojayeonjonghwan, an oriental medicine composed of five seeds, protects against vasomotor and neurological disorders in estrogen-deficient rats Article Snippet: Article Title: Implementation of an Enzyme Membrane Reactor to Intensify the α- O -Glycosylation of Resveratrol Using Cyclodextrins Article Snippet: Resveratrol, piceid and High Performance Liquid Chromatography:Article Title: Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells. Article Snippet: Several genetic, molecular, and cellular mechanisms leading to oxidative stress, mitochondrial dysfunction, and apoptosis have been shown to contribute to dopamine (DA) neuronal dysfunction and its loss with normal aging and neurodegenerative diseases like Parkinson’s disease (PD) (Fahn and Cohen 1992; Lin and Beal 2006; Mattson and Magnus 2006; Rehman and Masson 2001; Shigenaga et al. 1994; Tanaka et al. 2012; Tatton et al. 2003).. However, the underlying mechanisms remain elusive.. Till date no drug therapy is available to halt the progressive loss of DA neurons that occurs in the aging brain. |


